COVID-19 in hematological malignancies: Case series and literature review.

Autor: Ocheni S; Department of Haematology and Immunology, University of Nigeria; Department of Haematology and Immunology, University of Nigeria Teaching Hospital, Ituku-Ozalla Campus, Enugu, Nigeria., Nwagha TU; Department of Haematology and Immunology, University of Nigeria; Department of Haematology and Immunology, University of Nigeria Teaching Hospital, Ituku-Ozalla Campus, Enugu, Nigeria., Amu N; Department of Haematology and Immunology, University of Nigeria Teaching Hospital, Ituku-Ozalla Campus, Enugu, Nigeria., Obodo OI; Department of Haematology and Immunology, University of Nigeria Teaching Hospital, Ituku-Ozalla Campus, Enugu, Nigeria., Okereke K; Department of Haematology and Immunology, University of Nigeria Teaching Hospital, Ituku-Ozalla Campus, Enugu, Nigeria., Chikezie K; Department of Haematology and Immunology, University of Nigeria Teaching Hospital, Ituku-Ozalla Campus, Enugu, Nigeria., Ejezie CS; Department of Haematology and Immunology, University of Nigeria Teaching Hospital, Ituku-Ozalla Campus, Enugu, Nigeria., Ilechukwu GU; Department of Haematology and Immunology, University of Nigeria Teaching Hospital, Ituku-Ozalla Campus, Enugu, Nigeria., Obiatuegwu C; Department of Haematology and Immunology, University of Nigeria Teaching Hospital, Ituku-Ozalla Campus, Enugu, Nigeria.
Jazyk: angličtina
Zdroj: Annals of African medicine [Ann Afr Med] 2023 Jul-Sep; Vol. 22 (3), pp. 381-384.
DOI: 10.4103/aam.aam_238_21
Abstrakt: Earlier reports suggest that cancer patients were twice more likely to contract severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this report, we describe two patients with hematological malignancies seen at the peak of the first wave of the coronavirus disease 2019 pandemic. A 61-year-old man was referred to our urology unit he was diagnosed with nodular hyperplasia and multiple myeloma and commenced on bortezomib, thalidomide, and dexamethasone combination chemotherapy. He developed a cough and fever, with SPO 2 86%, He was positive for SARS-CoV-2 and died a few days later. A 42-year-old man with Hodgkin lymphoma on treatment with Adriamycin, bleomycin, vincristine, and dacarbazine with positive SARS-CoV-2 exposure was diagnosed with pleural effusion at A/E. Three days postadmission, his condition worsened with low SPO 2 despite intranasal oxygen. He died after testing positive for SARS-CoV-2. Patients with hematological malignancies tend to have a greater risk of SARS-COV-2 infection and severe disease due to immunosuppression from cancer and its treatment.
Competing Interests: None
Databáze: MEDLINE
Externí odkaz: